Skip to main content

Japan AI Governance Framework: Implementing METI and MHLW Guidelines

Japan's AI governance model is guidance-led rather than built around one horizontal AI statute. For many businesses, the practical baseline is METI's AI Guidelines for Business together with broader privacy and sectoral obligations such as the Act on the Protection of Personal Information. In healthcare and clinical-support scenarios, MHLW guidance and PMDA expectations create a much stricter operating model around validation, accountability, and professional review. Keeptrusts cannot obtain PMDA approval, prove clinical effectiveness, or determine whether a workflow is regulated as software as a medical device. It can make the runtime side of the control stack real: redact sensitive data, restrict which providers can receive requests, reject unsupported outputs, and force human review on routes that should never behave like straight-through automation.

Use this page when​

  • You need to turn Japan's guidance-heavy AI governance model into concrete route controls.
  • You are separating general business assistants from MHLW-sensitive healthcare or clinical-support workflows.
  • You want precise language about what Keeptrusts does today versus what still belongs to validation, quality, and legal teams.

Primary audience​

  • Primary: Compliance officers, healthcare platform owners, engineering leads
  • Secondary: privacy officers, security engineers, medical informatics teams

The problem​

Guidance-led governance creates a predictable implementation gap. Teams read soft-law documents, agree with the principles, and then fail to define a route-specific runtime boundary. A company ends up with one assistant stack for everything from internal productivity to patient-facing support to clinical-summary generation. That is operationally convenient and legally weak.

The failure is not that METI or MHLW guidance is too abstract. The failure is that organizations do not translate those expectations into technical distinctions. A route that drafts product copy does not need the same control model as a route that summarizes patient information for a clinician. A route that supports internal research can tolerate different latency and review patterns than a route that may influence diagnosis, treatment, or other medical judgment.

APPI adds another pressure point. Personal information and, in many cases, sensitive medical context should not travel to a broad or weakly governed provider set just because a general AI platform makes that easy. When a route handles names, identifiers, or clinical facts, minimizing and constraining that flow matters before anyone debates model quality.

The final gap is accountability. A simple record that a model was called does not show that a clinician-reviewed path existed, that unsupported outputs were blocked, or that the relevant route was isolated from general office traffic.

The solution​

The cleanest implementation pattern is to maintain at least two governance lanes.

The first lane is ordinary business AI. This is where METI-style expectations around governance, transparency, provider selection, and incident readiness can often be met with lighter controls. You still want route ownership, provider restrictions where appropriate, and evidence, but you usually do not need to stop every output for manual review.

The second lane is MHLW-sensitive or clinically consequential traffic. Here the technical posture should be more conservative. pii-detector reduces exposed personal and healthcare-adjacent text before upstream processing. data-routing-policy narrows the eligible provider set to the operators your organization has actually reviewed for retention and training posture. quality-scorer and citation-verifier improve the value of material that reaches a reviewer by rejecting obviously weak or unsupported outputs. human-oversight then creates the hard stop: the route escalates instead of returning normal assistant content.

That last control needs precise wording. Current human-oversight behavior is route-level escalation. If you set action: escalate, the gateway does not deliver the assistant output normally. It returns an escalated result and emits the corresponding decision event. That is a good fit for clinical-support or high-impact review flows. It is a bad fit for ordinary drafting or search assistance. Route isolation matters because the control is intentionally strong.

You should also keep validation boundaries clear. Keeptrusts can help ensure that unsupported or poorly structured output does not move downstream. It does not replace clinical evaluation, dataset governance, medical-device review, hospital approval processes, or professional obligations around final judgment.

Implementation​

For a conservative clinical-support route, use a dedicated configuration rather than bolting healthcare review onto a general assistant.

pack:
  name: japan-clinical-support
  version: "1.0.0"
  enabled: true

providers:
  targets:
    - id: reviewed-medical-provider
      provider: openai
      model: gpt-5.4-mini-mini
      secret_key_ref:
        env: OPENAI_API_KEY
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0
        allow_internet_egress: false

policies:
  chain:
    - pii-detector
    - data-routing-policy
    - quality-scorer
    - citation-verifier
    - human-oversight
    - audit-logger

policy:
  pii-detector:
    action: redact
    healthcare_mode: true
    redaction:
      marker_format: label
      include_metadata: true

  data-routing-policy:
    require_zero_data_retention: true
    require_no_training: true
    max_retention_days: 0
    allow_internet_egress: false
    on_no_compliant_provider: block
    log_provider_selection: true

  quality-scorer:
    min_output_chars: 120
    min_sentences: 2

  citation-verifier:
    require_sources: true
    require_source_match: true
    output_action:
      unverified_action: block

  human-oversight:
    action: escalate

  audit-logger: {}

This route does three useful things. It minimizes patient and personal text before provider handling, rejects unsupported output instead of forwarding it to a clinician queue, and then forces all remaining outputs into a review workflow rather than direct delivery.

That is still not the full Japanese governance package. If the use case is in or near regulated medical-device territory, you still need the validation evidence, role assignments, approval history, and clinical governance structures that MHLW and PMDA expectations imply. If the route is only general internal business assistance, this exact configuration is probably too restrictive and should be replaced by a lighter chain.

The design principle is proportionality. Use a heavier route when the workflow could shape clinical or other high-consequence action. Use a lighter route when the assistant is just supporting internal drafting, research, or summarization without direct patient or decision impact.

The most relevant companion pages are Configuration & Policy Overview, PII Detector, Data Routing Policy, Compliance Officer Guide, and Zero-Trust AI.

Results and impact​

When Japan-focused teams separate these lanes, the governance discussion gets clearer. METI-style business governance becomes the baseline for route ownership, provider discipline, and evidence. MHLW-sensitive workloads get a distinct runtime posture with stronger review and evidence expectations. That is much easier to defend than a single assistant platform with verbal warnings attached to it.

It also makes incident response better. If an unsupported output appears on a route that should have been clinically reviewed, you know immediately that the route design failed. If a personal-data-heavy route uses the wrong provider set, data-routing-policy failure is visible rather than hidden in application code.

Most importantly, it avoids overclaiming. Keeptrusts can operationalize the runtime controls around Japanese AI governance. It does not replace medical validation, product approval, or legal classification.

Key takeaways​

  • Japan's AI governance is guidance-led, so route design matters more than slogans about being "responsible by default."
  • Separate general business routes from MHLW-sensitive healthcare or clinical-support routes.
  • Use pii-detector and data-routing-policy to narrow sensitive data exposure before upstream processing.
  • Current human-oversight behavior is a full route-level escalation stop, which is useful for high-consequence review workflows.
  • Validation, clinical effectiveness, and regulated-device questions stay outside the gateway.

Next steps​